Enhanced binding of the hypoxic cell marker [3H]fluoromisonidazole in ischemic myocardium

G. V. Martin, J. H. Caldwell, J. S. Rasey, Z. Grunbaum, M. Cerqueira, Kenneth Krohn

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

The 2-nitroimidazole fluoromisonidazole is metabolically trapped in viable hypoxic cells in inverse proportion to PO2. This attribute suggests that [18F]fluoromisonidazole may be useful for imaging hypoxic tissue using positron emission tomography. To examine this potential, we studied the pharmacokinetics and biodistribution of [3H]fluoromisonidazole in six open chest dogs. In two normal dogs, plasma and urine samples were collected over a 4-hr period following i.v. injection of the drug. In four animals, regional myocardial ischemia was produced 2 hr prior to drug injection by occlusion of the circumflex coronary artery and maintained during the 4-hr sampling period. In all animals, postmortem samples of myocardium and other organs were obtained and tissue, plasma, and urine tritium activity were determined by liquid scintillation counting. In areas of reduced flow, [3H]fluoromisonidazole accumulated in myocardium in inverse proportion to myocardial blood flow mesured by microspheres, indicating enhanced binding in hypoxic tissues. Maximum tissue concentrations in ischemic myocardium were two- to three-fold greater than in normal myocardium and plasma. Plasma clearance data indicate the drug is rapidly distributed into the total-body water, clears from the body with a half-life of 275 ± 50 min, and undergoes minimal metabolism by 4 hr. We conclude [18F]fluoromisonidazole may be a suitable agent for radionuclide imaging of hypoxic myocardium.

Original languageEnglish (US)
Pages (from-to)194-201
Number of pages8
JournalJournal of Nuclear Medicine
Volume30
Issue number2
StatePublished - 1989
Externally publishedYes

Fingerprint

Myocardium
Urine
Pharmaceutical Preparations
Dogs
Scintillation Counting
Injections
Tritium
Body Water
Microspheres
Radionuclide Imaging
Positron-Emission Tomography
Myocardial Ischemia
Half-Life
Coronary Vessels
Thorax
Pharmacokinetics
fluoromisonidazole

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Martin, G. V., Caldwell, J. H., Rasey, J. S., Grunbaum, Z., Cerqueira, M., & Krohn, K. (1989). Enhanced binding of the hypoxic cell marker [3H]fluoromisonidazole in ischemic myocardium. Journal of Nuclear Medicine, 30(2), 194-201.

Enhanced binding of the hypoxic cell marker [3H]fluoromisonidazole in ischemic myocardium. / Martin, G. V.; Caldwell, J. H.; Rasey, J. S.; Grunbaum, Z.; Cerqueira, M.; Krohn, Kenneth.

In: Journal of Nuclear Medicine, Vol. 30, No. 2, 1989, p. 194-201.

Research output: Contribution to journalArticle

Martin, GV, Caldwell, JH, Rasey, JS, Grunbaum, Z, Cerqueira, M & Krohn, K 1989, 'Enhanced binding of the hypoxic cell marker [3H]fluoromisonidazole in ischemic myocardium', Journal of Nuclear Medicine, vol. 30, no. 2, pp. 194-201.
Martin, G. V. ; Caldwell, J. H. ; Rasey, J. S. ; Grunbaum, Z. ; Cerqueira, M. ; Krohn, Kenneth. / Enhanced binding of the hypoxic cell marker [3H]fluoromisonidazole in ischemic myocardium. In: Journal of Nuclear Medicine. 1989 ; Vol. 30, No. 2. pp. 194-201.
@article{a75c8abac63f49668296e919a196a541,
title = "Enhanced binding of the hypoxic cell marker [3H]fluoromisonidazole in ischemic myocardium",
abstract = "The 2-nitroimidazole fluoromisonidazole is metabolically trapped in viable hypoxic cells in inverse proportion to PO2. This attribute suggests that [18F]fluoromisonidazole may be useful for imaging hypoxic tissue using positron emission tomography. To examine this potential, we studied the pharmacokinetics and biodistribution of [3H]fluoromisonidazole in six open chest dogs. In two normal dogs, plasma and urine samples were collected over a 4-hr period following i.v. injection of the drug. In four animals, regional myocardial ischemia was produced 2 hr prior to drug injection by occlusion of the circumflex coronary artery and maintained during the 4-hr sampling period. In all animals, postmortem samples of myocardium and other organs were obtained and tissue, plasma, and urine tritium activity were determined by liquid scintillation counting. In areas of reduced flow, [3H]fluoromisonidazole accumulated in myocardium in inverse proportion to myocardial blood flow mesured by microspheres, indicating enhanced binding in hypoxic tissues. Maximum tissue concentrations in ischemic myocardium were two- to three-fold greater than in normal myocardium and plasma. Plasma clearance data indicate the drug is rapidly distributed into the total-body water, clears from the body with a half-life of 275 ± 50 min, and undergoes minimal metabolism by 4 hr. We conclude [18F]fluoromisonidazole may be a suitable agent for radionuclide imaging of hypoxic myocardium.",
author = "Martin, {G. V.} and Caldwell, {J. H.} and Rasey, {J. S.} and Z. Grunbaum and M. Cerqueira and Kenneth Krohn",
year = "1989",
language = "English (US)",
volume = "30",
pages = "194--201",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "2",

}

TY - JOUR

T1 - Enhanced binding of the hypoxic cell marker [3H]fluoromisonidazole in ischemic myocardium

AU - Martin, G. V.

AU - Caldwell, J. H.

AU - Rasey, J. S.

AU - Grunbaum, Z.

AU - Cerqueira, M.

AU - Krohn, Kenneth

PY - 1989

Y1 - 1989

N2 - The 2-nitroimidazole fluoromisonidazole is metabolically trapped in viable hypoxic cells in inverse proportion to PO2. This attribute suggests that [18F]fluoromisonidazole may be useful for imaging hypoxic tissue using positron emission tomography. To examine this potential, we studied the pharmacokinetics and biodistribution of [3H]fluoromisonidazole in six open chest dogs. In two normal dogs, plasma and urine samples were collected over a 4-hr period following i.v. injection of the drug. In four animals, regional myocardial ischemia was produced 2 hr prior to drug injection by occlusion of the circumflex coronary artery and maintained during the 4-hr sampling period. In all animals, postmortem samples of myocardium and other organs were obtained and tissue, plasma, and urine tritium activity were determined by liquid scintillation counting. In areas of reduced flow, [3H]fluoromisonidazole accumulated in myocardium in inverse proportion to myocardial blood flow mesured by microspheres, indicating enhanced binding in hypoxic tissues. Maximum tissue concentrations in ischemic myocardium were two- to three-fold greater than in normal myocardium and plasma. Plasma clearance data indicate the drug is rapidly distributed into the total-body water, clears from the body with a half-life of 275 ± 50 min, and undergoes minimal metabolism by 4 hr. We conclude [18F]fluoromisonidazole may be a suitable agent for radionuclide imaging of hypoxic myocardium.

AB - The 2-nitroimidazole fluoromisonidazole is metabolically trapped in viable hypoxic cells in inverse proportion to PO2. This attribute suggests that [18F]fluoromisonidazole may be useful for imaging hypoxic tissue using positron emission tomography. To examine this potential, we studied the pharmacokinetics and biodistribution of [3H]fluoromisonidazole in six open chest dogs. In two normal dogs, plasma and urine samples were collected over a 4-hr period following i.v. injection of the drug. In four animals, regional myocardial ischemia was produced 2 hr prior to drug injection by occlusion of the circumflex coronary artery and maintained during the 4-hr sampling period. In all animals, postmortem samples of myocardium and other organs were obtained and tissue, plasma, and urine tritium activity were determined by liquid scintillation counting. In areas of reduced flow, [3H]fluoromisonidazole accumulated in myocardium in inverse proportion to myocardial blood flow mesured by microspheres, indicating enhanced binding in hypoxic tissues. Maximum tissue concentrations in ischemic myocardium were two- to three-fold greater than in normal myocardium and plasma. Plasma clearance data indicate the drug is rapidly distributed into the total-body water, clears from the body with a half-life of 275 ± 50 min, and undergoes minimal metabolism by 4 hr. We conclude [18F]fluoromisonidazole may be a suitable agent for radionuclide imaging of hypoxic myocardium.

UR - http://www.scopus.com/inward/record.url?scp=0024588935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024588935&partnerID=8YFLogxK

M3 - Article

C2 - 2738648

AN - SCOPUS:0024588935

VL - 30

SP - 194

EP - 201

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 2

ER -